Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis
CONCLUSION: Hepatic steatosis lowers the biochemical response to antiviral treatment in patients with CHB.PMID:38577526 | PMC:PMC10989305 | DOI:10.4254/wjh.v16.i3.465 (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Shi-Yi Liu Dian Wang Jing Liu Lu-Ping Yang Gong-Ying Chen Source Type: research
Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss
Conclusion
Transcriptionally active HBV integration occurred in chronically HBV-infected patients at different phases, including in patients with HBsAg loss. Antiviral treatment was associated with a decreased number and extent of transcriptionally active viral integrations, implying that early treatment intervention may further reduce the number of viral integration events. (Source: Gut)
Source: Gut - April 5, 2024 Category: Gastroenterology Authors: Yu, X., Gong, Q., Yu, D., Chen, Y., Jing, Y., Zoulim, F., Zhang, X. Tags: Open access, Gut Hepatology Source Type: research
Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey
ConclusionThis study highlights a 14% anti-HBc positivity, indicating a potential risk for HBV reactivation in people with MS receiving ocrelizumab. This suggests the importance of vigilant monitoring and the implementation of prophylactic measures. Our recommendation emphasizes antiviral prophylaxis, particularly for patients with low anti-HBs, and a pre-emptive strategy for others. (Source: Journal of Neurology)
Source: Journal of Neurology - April 5, 2024 Category: Neurology Source Type: research
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2
Functional cure (FC) for chronic hepatitis B (CHB) requires finite treatment. Two agents under investigation aimed at achieving FC are small interfering RNA JNJ-73763989 (JNJ-3989) and capsid assembly modulator JNJ-56136379 (JNJ-6379; bersacapavir). (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 4, 2024 Category: Gastroenterology Authors: Kosh Agarwal, Maria Buti, Florian van B ömmel, Pietro Lampertico, Ewa Janczewska, Marc Bourliere, Thomas Vanwolleghem, Oliver Lenz, Thierry Verbinnen, Thomas N. Kakuda, Cristiana Mayer, John Jezorwski, Daniel Muenz, Maria Beumont, Ronald Kalmeijer, Micha Tags: Research Article Source Type: research
Furanocoumarins promote proteasomal degradation of viral HBx protein and down-regulate cccDNA transcription and replication of hepatitis B virus
Virology. 2024 Mar 24;595:110065. doi: 10.1016/j.virol.2024.110065. Online ahead of print.ABSTRACTNucleot(s)ide analogues, the current antiviral treatments against chronic hepatitis B (CHB) infection, are non-curative due to their inability to eliminate covalently closed circular DNA (cccDNA) from the infected hepatocytes. Preclinical studies have shown that coumarin derivatives can effectively reduce the HBV DNA replication. We evaluated the antiviral efficacy of thirty new coumarin derivatives in cell culture models for studying HBV. Furanocoumarins Fc-20 and Fc-31 suppressed the levels of pre-genomic RNA as well as cccD...
Source: Virology - April 3, 2024 Category: Virology Authors: Purnima Tyagi Ankita Singh Jitendra Kumar Belal Ahmad Aparna Bahuguna Perumal Vivekanandan Shiv Kumar Sarin Vijay Kumar Source Type: research
